상세 보기
Durvalumab (D) and tremelimumab (T) as first-line treatment (tx) for participants (pts) with unresectable hepatocellular carcinoma (uHCC) and a poor prognosis: Primary efficacy and safety results from the phase IIIB SIERRA study
- Rimassa, L.;
- Kudo, M.;
- Sangro, B.;
- Kelley, R. k.;
- Kim, J. h.;
- ... Hong, J. y.;
- 외 13명
Citations
WEB OF SCIENCE
0- 제목
- Durvalumab (D) and tremelimumab (T) as first-line treatment (tx) for participants (pts) with unresectable hepatocellular carcinoma (uHCC) and a poor prognosis: Primary efficacy and safety results from the phase IIIB SIERRA study
- 저자
- Rimassa, L.; Kudo, M.; Sangro, B.; Kelley, R. k.; Kim, J. h.; Van Binh, P.; Hong, J. y.; Waldschmidt, D. t.; Marino, D.; Gerolami, R.; Burgoyne, A.; Masi, G.; Walsh, R. j.; Marquardt, J. u.; Emeribe, U.; Balaji, K.; Sun, P.; Baur, B.; Chan, S. l.
- 발행일
- 2026-07
- 유형
- Meeting Abstract
- 권
- 37
- 페이지
- S82 ~ S83
- 언어
- ENG
- 출판사
- ELSEVIER
- 발행국가
- 네덜란드
- ISSN
- E 1569-8041
P 0923-7534